Company intelligence / Profile preview

ImmunoForge

Ownership: Private
Development stage: Phase 2

Overview

ImmunoForge specializes in developing novel drugs for rare and intractable diseases using its proprietary ELP platform to extend drug half-life. Its lead asset, Froniglutide, has reached Phase II clinical trials for polymyositis/dermatomyositis. The company also develops therapies for DMD and rare cancers such as drug-resistant CML. It has received multiple grants and orphan drug designations from the US FDA.

Therapeutic areas: GastroenterologyOncologyRare DiseasesRheumatology
Modalities: Recombinant polypeptidesBiological productsSmall moleculesSynthetic peptides
Industry: Biotech

Drug pipeline

8 assets

pemziviptadil

7 more assets in the full pipeline.

Partnerships

Dong-A ST Co. Ltd.NeuroBo Pharmaceuticals Inc.Duke UniversityMaterial Transfer Agreement with Korea University.

Beyond the preview

Go deeper on ImmunoForge.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmunoForge.